Skip to content
Screener

Viridian Therapeutics, Inc. VRDN Common Stock Shares Issued

Common Stock Shares Issued at other companies

Immunovant, Inc. logo
Immunovant, Inc.IMVT
203.3M+38.1%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
60.9M+7.5%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
100.7M+110%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
29.4M+1.9%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
255.3M+21.6%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
132.9M+0.2%

Other financials

Income statement

See full
Revenue$284.0K+279%
Operating income-$126.3M-18.3%
Net income-$127.1M-26.2%
EPS (diluted)-$1.15-5.5%

Balance sheet

See full
Cash & equivalents$165.0M+40.6%
Total debt$114.4M+395%
Total equity$662.1M+28.5%
Total assets$1.1B+88.4%

Cash flow

See full
Operating cash flow-$105.3M-39.7%
CapEx$1.3M+3,010%
Free cash flow-$106.6M-41.4%

Valuation

See full
Market cap$2.61B+89.4%
Enterprise value$2.56B+99.4%
P/S36.7×-4,485×

Profitability

See full
Gross margin36.3%
Operating margin-569.7%-284pp
Net margin-544.1%-271pp
FCF margin-471%-235pp

Returns & leverage

See full
Return on equity-65.7%-0.1pp
Debt / equity0.2×+0.1×
Current ratio16.9×+5.9×

Where this comes from

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.

The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:31 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001590750-26-000018
Line itemJune 30,2026December 31,2025
Stockholders’ equity:
Preferred stock, series A non-voting convertible preferred stock, $0.01 par value; 435,000 shares authorized; 133,191 and 134,864 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively60,43261,188
Preferred stock, series B non-voting convertible preferred stock, $0.01 par value; 500,000 shares authorized; 48,463 and 79,620 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively37,59270,868
Common stock, $0.01 par value; 200,000,000 shares authorized; 113,238,218 and 101,826,500 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively1,1321,018
Additional paid-in capital2,134,5721,927,104
Accumulated other comprehensive income (loss)(1,153)447
Accumulated deficit(1,570,478)(1,338,458)
Total stockholders’ equity662,097722,167

Item 1. Financial Statements (Unaudited)

FAQ

What is Viridian Therapeutics, Inc.'s common stock shares issued?
Viridian Therapeutics, Inc. (VRDN) reported common stock shares issued of 113.2M in Q2 2026.
How has Viridian Therapeutics, Inc.'s common stock shares issued changed year-over-year?
Viridian Therapeutics, Inc.'s common stock shares issued increased by 38.7% year-over-year, from 81.7M to 113.2M.
What is the long-term trend for Viridian Therapeutics, Inc.'s common stock shares issued?
Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s common stock shares issued has grown at a 88.9% compound annual growth rate (CAGR), from 4.2M to 101.8M.
What does common stock shares issued mean?
The total number of shares that have been authorized and distributed by the corporation since its inception. This includes shares held by the public (outstanding) as well as any shares that the company has repurchased and holds in its treasury. It represents the historical volume of equity capital creation.

Ask your AI about Viridian Therapeutics, Inc.'s common stock shares issued.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude